Table 3.
Up-regulated (in bold) and down-regulated (normal letters) lncRNAs in CSCC.
| lncRNAs (Function) | Gene Targets | Mechanisms | Drug Sensitivity (S)/Drug Resistance (R) in Other Cancer Models |
|---|---|---|---|
|
MALAT1 (Oncogene) |
c-MYC gene | Induction of tumor progression by up-regulating EGFR expression and activating the MAPK, PI3K and KRAS pathway [38]. | (R) Cisplatin [122,123,124,125,126,127,128] (R)5-FU [129,130] |
|
THOR (Oncogene) |
IGF2BP1 gene | Induction of cancer progression by targeting the RNA-binding protein IGF2BP1 [131]. | (R)Cisplatin [132] |
|
HOTAIR (Oncogene) |
miR-326 | Promotion of cell proliferation and migration in vitro and tumor growth in vivo by up-regulating PRAF2 expression by sponging miR-326 [43]. | (R) Cisplatin [133,134,135,136] (R) 5-FU [137,138,139] (R) Doxorubicin [140,141,142] |
|
LINC00319 (Oncogene) |
miR-1207-5p | Promotion of cell proliferation, migration, invasiveness and the inhibition of apoptosis by up-regulating the expression of CDK3, a miR-1207-5 p target gene [46]. | No data available |
|
LINC00963 (Oncogene) |
miR-1193 | Inhibition of miR-1193 expression by promoting SOX4 expression and cancer progression [47]. | No data available |
|
LINC01048 (Oncogene) |
Transcription factor TAF15 | Induction of cell proliferation by up-regulating YAP1 oncogene transcription and modulating the apoptosis-related proteins expression [143]. | No data available |
|
LINC00162 or PICSAR (Oncogene) |
DUSP6, α2β1 and α5β1 integrin gene | Increase of cell proliferation and migration by down-regulating both the expression of a specific ERK2 phosphatase (DUSP6) and of the α2β1 and α5β1 integrins [29,144]. | No data available |
|
LINC00346 or PRECSIT (Oncogene) |
Transcription factor STAT3 | Induction of cell migration and invasion by up-regulating MMP-1, MMP-3, MMP-10 and MMP-13 expression [28]. | (R) Cisplatin[145] |
| TINCR (Tumor suppressor) |
Not mentioned | Induction of apoptosis and cell autophagy [146]. | No data available |
| LINC00520 (Tumor suppressor) |
EGFR gene | Inhibition of EGFR expression by inactivating the PI3K-Akt pathway and preventing the tumor progression [37]. | No data available |